Sanofi (SNY) Stock Score, Valuation & Financial Research
Sanofi is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 57/100.
Quick answer for SNY
Sanofi currently has a Wall Street Score of 57/100. The stored market price is $42.4. Its financial score is 34/100. Its valuation score is 85/100. These figures are a research snapshot, not a buy or sell recommendation.
What Sanofi does
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomy
SNY financial snapshot
- Wall Street Score:
- 57/100
- Current price:
- $42.4
- Market capitalization:
- $101.81B
- Revenue:
- $53.92B
- Net income:
- $8.60B
- Free cash flow:
- $11.55B
- Cash:
- $6.31B
- Total debt:
- $22.80B
- EPS:
- 3.64
- P/E ratio:
- 11.6x
- Financial score:
- 34/100
- Valuation score:
- 85/100
- Revenue score:
- 26/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $11.55B, showing positive cash generation.
- The balance sheet shows $6.31B of cash versus $22.80B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 85/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 34/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SNY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.